From: Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Drug name | Targets | Development stage | Clinical trial identifier | Company |
---|---|---|---|---|
LOXO-101 (larotrectinib) | NTRK1/2/3 | Phase II | NCT02122913 NCT02637687 NCT02576431 NCT03213704 | Loxo Oncology |
LOXO-195 | NTRK1/2/3 (resistant) | Phase I/II | NCT03215511 | Loxo Oncology |
RXDX-101 (entrectinib) | NTRK1/2/3, ALK, ROS1 | Phase I/II, Phase II, Phase I/Ib | NCT02097810 NCT02568267 NCT02650401 | Ignyta |
TPX-0005 (ropotrectinib) | NTRK1/2/3, ALK, ROS1 (resistant), JAK2, SRC, DDR1, FAK | Phase I/II | NCT03093116 | TP Therapeutics |
LY2801653 (merestinib) | NTRK1/2/3, MET, MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2, MKNK1/2 | Phase II | NCT02920996 | Eli Lilly and Company |
DS-6051b | NTRK1/2/3, ROS1 | Phase I | NCT02675491 NCT02279433 | Daiichi Sankyo |
PLX7486 | NTRK1/2/3, CSF1R | Phase I | NCT01804530 | Plexxikon/Daiichi Sankyo |
MGCD516 (sitravatinib) | NTRK1/2/3, MET, KIT, PDGFRA, KDR, DDR2, RET, CBL | Phase I/Ib | NCT02219711 | Mirati Therapeutics |